In vitro studies of Gynura divaricata (L.) DC extracts as inhibitors of key enzymes relevant for type 2 diabetes and hypertension

2011 ◽  
Vol 136 (2) ◽  
pp. 305-308 ◽  
Author(s):  
Tingting Wu ◽  
Xueting Zhou ◽  
Yafei Deng ◽  
Qing Jing ◽  
Min Li ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
In Vitro Studies ◽  
Key Enzymes

Boerhaavia diffusa inhibits key enzymes linked to type 2 diabetes in vitro and in silico; and modulates abdominal glucose absorption and muscle glucose uptake ex vivo

2018 ◽  
Vol 106 ◽  
pp. 1116-1125 ◽  
Author(s):  
Olajumoke A. Oyebode ◽  
Ochuko L. Erukainure ◽  
Chika I. Chukwuma ◽  
Collins U. Ibeji ◽  
Neil A. Koorbanally ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Glucose Uptake ◽  
In Silico ◽  
Ex Vivo ◽  
Glucose Absorption ◽  
Key Enzymes ◽  
Boerhaavia Diffusa

scholarly journals Resistin and Type 2 Diabetes: Regulation of Resistin Expression by Insulin and Rosiglitazone and the Effects of Recombinant Resistin on Lipid and Glucose Metabolism in Human Differentiated Adipocytes

2003 ◽  
Vol 88 (12) ◽  
pp. 6098-6106 ◽  
Author(s):  
Philip G. McTernan ◽  
FFolliott M. Fisher ◽  
George Valsamakis ◽  
Rajkumar Chetty ◽  
Alison Harte ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Glucose Uptake ◽  
Protein Secretion ◽  
In Vitro Studies ◽  
Dependent Manner ◽  
Diabetes Status ◽  
Human Diabetes ◽  
Type 2 Diabetic

Abstract Resistin, an adipocyte secreted factor, has been suggested to link obesity with type 2 diabetes in rodent models, but its relevance to human diabetes remains uncertain. Although previous studies have suggested a role for this adipocytokine as a pathogenic factor, its functional effects, regulation by insulin, and alteration of serum resistin concentration by diabetes status remain to be elucidated. Therefore, the aims of this study were to analyze serum resistin concentrations in type 2 diabetic subjects; to determine the in vitro effects of insulin and rosiglitazone (RSG) on the regulation of resistin, and to examine the functional effects of recombinant human resistin on glucose and lipid metabolism in vitro. Serum concentrations of resistin were analyzed in 45 type 2 diabetic subjects and 34 nondiabetic subjects. Subcutaneous human adipocytes were incubated in vitro with insulin, RSG, and insulin in combination with RSG to examine effects on resistin secretion. Serum resistin was increased by approximately 20% in type 2 diabetic subjects compared with nondiabetic subjects (P = 0.004) correlating with C-reactive protein. No other parameters, including adiposity and fasting insulin levels, correlated with serum resistin in this cohort. However, in vitro, insulin stimulated resistin protein secretion in a concentration-dependent manner in adipocytes [control, 1215 ± 87 pg/ml (mean ± sem); 1 nm insulin, 1414.0 ± 89 pg/ml; 1 μm insulin, 1797 ± 107 pg/ml (P < 0.001)]. RSG (10 nm) reduced the insulin-mediated rise in resistin protein secretion (1 nm insulin plus RSG, 971 ± 35 pg/ml; insulin, 1 μm insulin plus RSG, 1019 ± 28 pg/ml; P < 0.01 vs. insulin alone). Glucose uptake was reduced after treatment with 10 ng/ml recombinant resistin and higher concentrations (P < 0.05). Our in vitro studies demonstrated a small, but significant, reduction in glucose uptake with human recombinant resistin in differentiated preadipocytes. In human abdominal sc adipocytes, RSG blocks the insulin-mediated release of resistin secretion in vitro. In conclusion, elevated serum resistin in human diabetes reflects the subclinical inflammation prevalent in type 2 diabetes. Our in vitro studies suggest a modest effect of resistin in reducing glucose uptake, and suppression of resistin expression may contribute to the insulin-sensitizing and glucose-lowering actions of the thiazolidinediones.

scholarly journals Assessing the In Vitro Inhibitory Effects on Key Enzymes Linked to Type-2 Diabetes and Obesity and Protein Glycation by Phenolic Compounds of Lauraceae Plant Species Endemic to the Laurisilva Forest

Molecules ◽  
2021 ◽  
Vol 26 (7) ◽  
pp. 2023
Author(s):  
Vítor Spínola ◽  
Paula C. Castilho
Keyword(s):  
Type 2 Diabetes ◽  
Protein Glycation ◽  
Inhibitory Effects ◽  
Leaf Extracts ◽  
Key Enzymes ◽  
Glycation End Products ◽  
First Time ◽  
Diabetes And Obesity

Methanolic leaf extracts of four Lauraceae species endemic to Laurisilva forest (Apollonias barbujana, Laurus novocanariensis, Ocotea foetens and Persea indica) were investigated for the first time for their potential to inhibit key enzymes linked to type-2 diabetes (α-amylase, α-glucosidase, aldose reductase) and obesity (pancreatic lipase), and protein glycation. Lauraceae extracts revealed significant inhibitory activities in all assays, altough with different ability between species. In general, P. indica showed the most promissing results. In the protein glycation assay, all analysed extracts displayed a stronger effect than a reference compound: aminoguanidine (AMG). The in vitro anti-diabetic, anti-obesity and anti-glycation activities of analysed extracts showed correlation with their flavonols and flavan-3-ols (in particular, proanthocyanins) contents. These Lauraceae species have the capacity to assist in adjuvant therapy of type-2 diabetes and associated complications, through modulation of the activity of key metabolic enzymes and prevention of advanced glycation end-products (AGEs) formation.

Sign in / Sign up

Export Citation Format

Share Document